Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
Authors:
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 12, 44-48
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81501849, 81201385)
- Medical Science and Technology Development (ZKX14021)
This publication has 24 references indexed in Scilit:
- The Role of theMTHFRC677T Polymorphism in Methotrexate-Induced Toxicity in Pediatric Osteosarcoma PatientsPharmacogenomics, 2017
- The role of pharmacogenetics in the treatment of osteosarcomaDrug Discovery Today, 2016
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Systematic identification of trans eQTLs as putative drivers of known disease associationsNature Genetics, 2013
- ABCB1 C3435T Genetic Polymorphism on Population Pharmacokinetics of Methotrexate After Hematopoietic Stem Cell Transplantation in Korean Patients: A Prospective AnalysisClinical Therapeutics, 2012
- Osteosarcoma in adolescents and adults: survival analysis with and without lung metastasesAnnals of Oncology, 2009
- High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesionsJournal of Surgical Oncology, 2008
- Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapyActa Oncologica, 2005
- Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell lineCell Death & Differentiation, 2003
- A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in the FasL Gene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus PatientsThe Journal of Immunology, 2003